Ken Simon

Ken has over 20 years’ of experience focused on the development of biotherapeutics for oncology, neurology, autoimmunity, fibrosis, and infectious disease. He received his Ph.D. degree in Molecular and Cellular Biology from SUNY Stonybrook and Cold Spring Harbor Laboratory and completed his postdoctoral training at the Salk Institute. He previously worked at Biogen and Abbvie Pharmaceuticals where he gained extensive experience in biologics drug development ranging from target identification and discovery to IND approval and post-marketing risk mitigation. Prior to joining Revitope, Ken was the Director of Biology at Tilos Therapeutics where he was responsible for the design and implementation of studies assessing the efficacy of monoclonal antibodies for immuno-oncology indications. He has extensive experience in antibody discovery as well as antibody engineering in order to improve the molecular characteristics of biologics for clinical use. He has over 25 publications in prestigious scientific journals and 11 patents/patent applications.